Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.62 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.62 |
| ▸ | GLP1R | P43220 | 9/20 | 0.58 |
| ▸ | GIPR | P48546 | 7/20 | 0.58 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.58 |
| ▸ | GCGR | P47871 | 4/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | NPY4R | P50391 | 1/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.56 |
| ▸ | CALCA | P06881 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593275 | 0.96 | C5AR1 (0.67) | CXCR4C5AR1GLP1RGIPRIL23R | |
| SCHEMBL29412272 | 0.89 | CXCR4 (0.66) | CXCR4GLP1RGIPRGCGRNPY1R | |
| SCHEMBL31593382 | 0.88 | CXCR4 (0.62) | CXCR4C5AR1 | |
| Cecropin Ad SCHEMBL29842479 | 0.88 | NPY1R (0.68) | GLP1RGIPRGCGRNPY1RNPY2R | |
| SCHEMBL29500420 | 0.88 | IL23R (0.68) | CXCR4C5AR1GLP1RGIPRIL23R | |
| SCHEMBL30974626 | 0.87 | CXCR4 (0.60) | CXCR4C5AR1GLP1RGCGRNPY1R | |
| SCHEMBL30575223 | 0.87 | C5AR1 (0.64) | CXCR4C5AR1IL23RNPY1RNPY2R | |
| SCHEMBL31593303 | 0.87 | CXCR4 (0.59) | CXCR4C5AR1IL23RCALCA | |
| SCHEMBL31593257 | 0.87 | CXCR4 (0.59) | CXCR4C5AR1IL23RCALCA | |
| SCHEMBL31593258 | 0.87 | IL23R (0.72) | IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | CXCR4 2331/4885C5AR1 704/4885GLP1R 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.